comprehensive -WSS

comprehensive

author：focus 2025-09-06 06:16:47 - browse：73694

Launching your first clinical trial is the type of announcement most biotech executives eagerly anticipate, hoping to celebrate with employees. But for Celsius Therapeutics CEO Tariq Kassum, it’s proving to be more difficult than he anticipated.

That’s because in recent days, Celsius, based in Cambridge, Mass., has been forced to conduct a round of layoffs, sources told STAT. Kassum confirmed around 75% of Celsius’ 40-person team had been laid off, and disclosed that the biotech has also been quietly paring back its pipeline this year. It shut down almost all early-stage research projects, including pausing all of its cancer drug work, in order to conserve enough cash for the Phase 1 trial it announced this week.

“It’s an incredibly bittersweet moment.… The cognitive dissonance there is just really, really hard,” Kassum told STAT. “But I do think that you’re seeing a lot of other companies doing what we are, which is, as painful as it is, to focus on the nearest term value drivers, the things that can get to patients the quickest, and make the painful decisions that allow you to live to fight another day.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： H5N1 bird flu found in pasteurized milk: what we know

hotspot

WSS

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Measles policy set amid Florida outbreak alarms vaccine proponents

Cholera vaccine supply gets boost as demand surges globally

After traumatic brain injury, life support decisions can use more time

Medicare Advantage enrollment hits roughly 33.4 million

focus

comprehensive

knowledge

Anesthesiologist group: stop taking Ozempic before surgery

H5N1 bird flu virus started spreading in cows in Texas in December

Alkermes shareholders re

New study raises questions about niacin and heart health

Heart attack and stroke risk calculators need revising

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

United colonoscopy coverage change 'may cost lives,' doctors say

Opioid cravings were reduced by anti

23andMe had bad news about my health. I wish a person had delivered it

Flagship Pioneering startup Sonata Therapeutics lays off 21

Wikipedia

Congress may force more Covid

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Element Biosciences CEO lays out genome sequencing strategy

MD Anderson's Padmanee Sharma responds to research credit suit

MD Anderson's Padmanee Sharma responds to research credit suit

MultiPlan and major insurers sued for alleged medical price

hotspot

focus

hotspot

knowledge